News
18th U.S. Surgeon General Joins Scipher Medicine
Dr. Regina Benjamin to Advise on Access to Precision Medicine Driving Better Health Outcomes for Patients with Autoimmune Diseases OCTOBER...
Scipher Medicine and Ambry Genetics Partner to Bring Precision Medicine Test for Rheumatoid Arthritis to Market
PrismRA® first-of-its-kind molecular signature test validated in Ambry’s central laboratory. Partnership provides infrastructure for rapid scaling and patient accessibility.
Pioneering precision medicine in rheumatoid arthritis
Scipher Medicine is a spin-out of Northeastern University founded on the basis of, first, building a map of human biology...
New Strategy for Avoiding Waste and Improving Response for Highest Cost Therapies in Rheumatoid Arthritis
AMCP Science & Innovation Theater Webinar Speakers: James T. Kenney, MBA, RPh, President, JTKENNEY, LLC Alif Saleh, CEO, Scipher Medicine...
Scipher Medicine Announces Publication of Clinical Study Validating PrismRA, a Blood Test Predicting Non-Response to TNF Inhibitor Therapies in Patients with Rheumatoid Arthritis
PrismRA identifies patients 6.6 times less likely to respond to TNFi therapy JULY 28, 2020- WALTHAM, MA- (Business Wire)- Scipher Medicine,...
Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients
Abstract Objectives: For rheumatoid arthritis (RA) patients failing to achieve treatment targets with conventional synthetic disease-modifying antirheumatic drugs, tumor necrosis factor...